Core Points - Genflow Biosciences PLC has successfully raised £800,000 through the issuance of 42,105,263 new ordinary shares at a price of 1.9p per share, with each share accompanied by a warrant for future subscription [1] - The funds raised will support the advancement of Genflow's scientific programs and provide a cash runway for potential future licensing negotiations [1] - The company plans to apply for the admission of the new shares to trading, expected to be effective around March 11, 2026, increasing the total issued ordinary share capital to 535,653,205 shares [1] Financial Details - The subscription price for the new ordinary shares is set at 1.9p, with a total volume of 42,105,263 shares issued [1] - If all warrants are exercised, an additional 42,105,263 ordinary shares could be issued, raising up to another £800,000 [1] - The total number of voting rights in the company will be 535,653,205 following the admission of the new shares [1] Company Overview - Genflow Biosciences is a biotechnology company focused on developing gene therapies for age-related diseases, aiming to promote longer and healthier lives [1] - The company's lead compound, GF-1002, targets the SIRT6 gene and has shown promising preclinical results [1] - Genflow is currently conducting a 12-month proof-of-concept clinical trial for GF-1002 in aged dogs, which began in March 2025 [1]